InflaRx (IFRX) Total Debt (2020 - 2022)

InflaRx's (IFRX) quarterly Total Debt came in at $144451.4 in Q3 2022, up 3.86% quarter-over-quarter from $139078.0 in Q2 2022.

InflaRx (IFRX) Total Debt (2020 - 2022) Analysis & Trends

InflaRx has disclosed Total Debt across 3 years of filings, most recently posting $144451.4 for Q3 2022.

  • Total Debt for Q3 2022 came in at $144451.4, changed N/A year-over-year; the trailing twelve-month figure through Sep 2022 was $144451.4 (changed N/A YoY), and the FY2021 annual result was $158103.6, up 12.64% from the prior year.
  • Total Debt came in at $144451.4 for Q3 2022 at InflaRx, up from $139078.0 in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $432094.3 in Q1 2021 to a low of $139078.0 in Q2 2022.
  • The 3-year median for Total Debt is $147432.5 (2022), against an average of $187433.8.
  • Across the five-year window, Total Debt grew 12.64% in 2021 and plunged 65.88% in 2022, its largest moves.
  • InflaRx's Total Debt stood at $140364.7 in 2020, then advanced by 12.64% to $158103.6 in 2021, then declined by 8.63% to $144451.4 in 2022.
  • The last three Total Debt figures came in at $144451.4 (Q3 2022), $139078.0 (Q2 2022), and $147432.5 (Q1 2022), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Debt (Qtr)
1 Alterity Therapeutics 723,416.35 Bn 723,416.32 Bn - -
2 Belite Bio 57,340.00 Bn 57,340.00 Bn - -
3 Quantum Biopharma 19,125.08 Bn 19,125.08 Bn - -
4 Legend Biotech 3,262.00 Bn 3,261.71 Bn 242.10 Mn 319.10 Mn
5 Akari Therapeutics 1,789.67 Bn 1,789.67 Bn - -
6 Evaxion A 1,480.39 Bn 1,480.37 Bn - -
7 Psyence Biomedical 241.78 Bn 241.78 Bn - -
8 Vertex Pharmaceuticals 113.54 Bn 106.29 Bn 2.59 Bn -
9 Abivax 94.26 Bn 94.26 Bn - -
10 InflaRx 764.68 Mn 764.68 Mn 10,877.40 -

Historic Data

Download Data
DateValue
Sep 30, 2022 144,451.43
Jun 30, 2022 139,078.03
Mar 31, 2022 147,432.53
Dec 31, 2021 158,103.65
Jun 30, 2021 150,512.25
Mar 31, 2021 432,094.28
Dec 31, 2020 140,364.71